Citadel Advisors
MRNA icon

Citadel Advisors’s Moderna MRNA Stock Holding History

Citadel Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$183M Sell
3,602,000
-3,294,500
-48% -$154M 0.03% 491
2025
Q4 		$203M Buy
6,896,500
+463,600
+7% +$12.6M 0.03% 481
2025
Q3 		$166M Buy
6,432,900
+1,734,700
+37% +$48.4M 0.03% 560
2025
Q2 		$130M Buy
4,698,200
+766,800
+20% +$20.2M 0.02% 601
2025
Q1 		$111M Buy
3,931,400
+503,800
+15% +$17.9M 0.02% 632
2024
Q4 		$143M Buy
3,427,600
+1,276,300
+59% +$61M 0.02% 547
2024
Q3 		$144M Buy
2,151,300
+363,300
+20% +$33.4M 0.03% 502
2024
Q2 		$212M Sell
1,788,000
-26,800
-1% -$3.39M 0.04% 327
2024
Q1 		$193M Sell
1,814,800
-199,100
-10% -$20.1M 0.04% 388
2023
Q4 		$200M Sell
2,013,900
-777,600
-28% -$65.4M 0.04% 344
2023
Q3 		$288M Buy
2,791,500
+1,083,200
+63% +$121M 0.06% 205
2023
Q2 		$208M Sell
1,708,300
-701,800
-29% -$93.6M 0.04% 308
2023
Q1 		$370M Sell
2,410,100
-559,000
-19% -$92.2M 0.08% 146
2022
Q4 		$533M Buy
2,969,100
+550,600
+23% +$90M 0.12% 94
2022
Q3 		$286M Buy
2,418,500
+49,600
+2% +$7.53M 0.07% 201
2022
Q2 		$338M Sell
2,368,900
-1,349,600
-36% -$193M 0.09% 149
2022
Q1 		$641M Sell
3,718,500
-42,200
-1% -$7.1M 0.13% 75
2021
Q4 		$955M Buy
3,760,700
+841,900
+29% +$246M 0.2% 48
2021
Q3 		$1.12B Buy
2,918,800
+1,389,800
+91% +$513M 0.23% 41
2021
Q2 		$359M Sell
1,529,000
-1,037,800
-40% -$185M 0.08% 145
2021
Q1 		$336M Buy
2,566,800
+904,700
+54% +$131M 0.08% 154
2020
Q4 		$174M Buy
1,662,100
+4,700
+0.3% +$475K 0.05% 313
2020
Q3 		$117M Buy
1,657,400
+754,300
+84% +$52.6M 0.03% 381
2020
Q2 		$58M Buy
903,100
+363,200
+67% +$19.9M 0.02% 710
2020
Q1 		$16.2M Buy
539,900
+493,800
+1,071% +$11.4M 0.01% 1409
2019
Q4 		$902K Buy
46,100
+10,800
+31% +$192K ﹤0.01% 5790
2019
Q3 		$562K Sell
35,300
-18,200
-34% -$269K ﹤0.01% 6552
2019
Q2 		$783K Buy
53,500
+32,100
+150% +$689K ﹤0.01% 6101
2019
Q1 		$435K Buy
+21,400
New +$397K ﹤0.01% 7021

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's MRNA Position: Q1 2026 in Review

Citadel Advisors reduced its Moderna (MRNA) stake by 15% in Q1 2026, selling an estimated $4.17M and leaving 489,770 shares worth $24.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Citadel Advisors first reported a position in MRNA in Q1 2019 and has held it in 29 quarters since. The position peaked at $168M in Q2 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Citadel Advisors held 489,770 shares of Moderna worth $24.9M as of Q1 2026.
  • Citadel Advisors sold 89,360 Moderna shares in Q1 2026, an estimated $4.17M.
  • Moderna made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2063 holding.
  • Citadel Advisors first reported a position in Moderna in Q1 2019 and has held it in 29 quarters since.
  • Citadel Advisors's Moderna position peaked at $168M in Q2 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.